Contraindications and people who should use molotinib (Ojjaara) with caution

Molotinib, as a new kinase inhibitor developed by GlaxoSmithKline, has brought new treatment options to patients with myelofibrosis. However, there are some clear contraindications and people who need to use it with caution during its use. Patients need to pay special attention. This article will introduce it in detail.

1. Contraindications

This medication is strictly contraindicated in patients who are allergic to molotinib or any of its components. Anaphylaxis may include severe symptoms such as rash, difficulty breathing, swelling, and may even be life-threatening.

2. Use with caution

1. Molotinib may worsen the patient's elevation of ALT, AST and bilirubin, so patients with liver damage need to be particularly careful. Patients with severe hepatic impairment (Child-Pugh class C) should use this drug with caution because their livers are no longer able to effectively metabolize and excrete the drug, which may cause the drug to accumulate in the body and increase the risk of adverse reactions. Doctors should closely monitor patients' liver enzyme levels before starting molotinib and during treatment to ensure safety.

2. Molotinib may increase the viral load in patients with chronic hepatitis B virus (HBV) infection. Therefore, physicians should obtain hepatitis B serology data from patients before initiating treatment. If the patient is HBsAg-positive and/or total anti-HBc-positive, consider consulting a hepatologist about monitoring or prophylactic hepatitis B treatment.

3. Molotinib may increase the risk of serious and fatal infections, so doctors should evaluate patients for active infections before and during treatment. If infection is found, administration should be avoided or used with caution.

4. Malignant tumors (including lymphoma and solid tumors) have been reported in patients treated with otherJAK inhibitors. Therefore, molotinib should be used with particular caution in patients who are current or former smokers, and in patients with known malignancy (other than successfully treated non-melanoma skin cancer).

5. Molotinib may cause harm to the fetus. Therefore, patients should take effective contraceptive measures during treatment and for one week after stopping the drug. If you are pregnant or suspected to be pregnant, tell your healthcare provider immediately.

In summary, although molotinib provides a new treatment option for patients with myelofibrosis, the contraindications and cautionary regulations should be strictly observed during use to ensure patient safety. The doctor will develop a reasonable treatment plan based on the patient's specific situation.